Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Ftoem1/Cya
Common Name:
Fto-KO
Product ID:
S-KO-08473
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Fto-KO
Strain ID
KOCMP-26383-Fto-B6J-VA
Gene Name
Fto
Product ID
S-KO-08473
Gene Alias
mKIAA1752
Background
C57BL/6JCya
NCBI ID
26383
Modification
Conventional knockout
Chromosome
8
Phenotype
MGI:1347093
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Ftoem1/Cya mice (Catalog S-KO-08473) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000069718
NCBI RefSeq
NM_011936.2
Target Region
Exon 3
Size of Effective Region
~0.6 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Fto, also known as fat mass and obesity-associated protein, is the first reported RNA N6-methyladenosine (m6A) demethylase in eukaryotic cells. m6A is the most abundant mRNA internal modification, involved in regulating processes like alternative splicing, stability, and expression. Fto has been associated with multiple biological processes and diseases, with its role in adipogenesis and tumorigenesis being of particular interest [1].

Genome-wide association studies (GWAS) identified Fto single-nucleotide polymorphisms (SNPs) associated with obesity. In EC-specific Fto-deficient (EC FtoΔ/Δ) diabetic mice, there was less retinal vascular leakage and acellular capillary formation compared to EC Ftofl/fl diabetic mice, suggesting Fto's role in diabetes-induced vascular endothelial dysfunction [2]. In osteoporosis, pharmacological inhibition of Fto markedly altered bone mass, bone mineral density, and adipose tissue distribution [3]. In multiple myeloma, FTO promotes tumor-promoting and pro-metastatic effects, and its inhibition, especially combined with bortezomib, synergistically inhibited myeloma bone tumor formation and extramedullary spread in NOD-Prkdcem26Cd52il2rgem26Cd22/Nju (NCG) mice [4].

In conclusion, Fto, as an m6A demethylase, is involved in various biological processes. Through gene-knockout or conditional-knockout mouse models, its role in diseases such as obesity, diabetes-related vascular complications, osteoporosis, and multiple myeloma has been revealed. These findings contribute to understanding the molecular mechanisms of these diseases and may provide potential therapeutic targets.

References:

1. Azzam, Sarah Kassem, Alsafar, Habiba, Sajini, Abdulrahim A. 2022. FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms. In International journal of molecular sciences, 23, . doi:10.3390/ijms23073800. https://pubmed.ncbi.nlm.nih.gov/35409166/

2. Zhou, Chuandi, She, Xinping, Gu, Chufeng, Chen, Haibing, Zheng, Zhi. 2023. FTO fuels diabetes-induced vascular endothelial dysfunction associated with inflammation by erasing m6A methylation of TNIP1. In The Journal of clinical investigation, 133, . doi:10.1172/JCI160517. https://pubmed.ncbi.nlm.nih.gov/37781923/

3. Huang, Mei, Guo, Jianmin, Liu, Lifei, Chen, Xi, Zou, Jun. 2023. m6A demethylase FTO and osteoporosis: potential therapeutic interventions. In Frontiers in cell and developmental biology, 11, 1275475. doi:10.3389/fcell.2023.1275475. https://pubmed.ncbi.nlm.nih.gov/38020896/

4. Xu, Aoshuang, Zhang, Jiasi, Zuo, Liping, Sun, Chunyan, Hu, Yu. 2021. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner. In Molecular therapy : the journal of the American Society of Gene Therapy, 30, 1104-1118. doi:10.1016/j.ymthe.2021.12.012. https://pubmed.ncbi.nlm.nih.gov/34915192/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest